High-yield recombinant production of the semaglutide main chain P29 intermediate using SNAC-tagged enterokinase-cleavable fusion peptides

Qingyu Qi, Ge Gao, Guodong Li, Xianling Bian · 2026

Read High-yield recombinant production of the semaglutide main chain P29 intermediate using SNAC-tagged enterokinase-cleavable fusion peptides by Qingyu Qi, Ge Gao, Guodong Li, Xianling Bian (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0348509.txt.

Description

Qingyu Qi and three colleagues engineer a cheaper route to a blockbuster diabetes drug's core piece. Their 2026 study concerns semaglutide, the long-acting hormone mimic behind modern diabetes and obesity treatment. Making it industrially is expensive and low-yielding. The team targeted its main chain, a fragment called P29. They grew it inside cells as part of a larger fusion protein. The fusion carries a tag and a cutting site designed for a two-step release.

First, a nickel-assisted chemical cut trims the construct. Then the enzyme enterokinase snips the fragment free. The helical fusion partners were derived from semaglutide's own sequence, helping the chain fold and accumulate. High expression was the reported payoff. Semaglutide demand keeps straining global supply. A fermentation route that yields its core intermediate cheaply could lower manufacturing cost for a medicine millions now depend on weekly.

Catalog record

CREATORQingyu Qi, Ge Gao, Guodong Li, Xianling Bian
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE23873
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0348509

Browse the full library · About the Tower of Babel